Cambridge, UK, 20 June 2019 – Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference attendance and during summer 2019. CEO Dr Mike Romanos, CSO Dr Trevor Lawley and Head of Bioinformatics Dr Simon Harris will be presenting on commercial and scientific advances and opportunities in the fast-moving microbiome space: Cambridge Biotech […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2019-06-20 09:00:082020-05-26 14:54:06Microbiotica Presenting at Key Industry Events during Summer 2019
Genentech’s infectious diseases and immunology dealmaker speaks to Scrip about the significance of following the science when it comes to partnering. When reflecting on the licensing deals inked this year by biotech behemoth Genentech Inc., two really stand out: the June deal with microbiome company Microbiotica Ltd. to discover, develop and commercialize treatments for inflammatory […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2018-11-07 09:00:212020-05-26 14:54:10Genentech's Immunology/Infectious Disease Deal Maker On Following The Science
Cambridge, UK, 2 November 2018 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been named Life Sciences Company of the Year at the Cambridge Independent Awards, which took place last night at the Hilton Cambridge City Centre Hotel. Microbiotica was recognised for a year of continued development in the fast-growing […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2018-11-02 09:00:522020-05-26 14:33:04Microbiotica Wins Life Sciences Company of the Year at Cambridge Independent Awards
Cambridge, UK, 30 October 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it will join the microbiome panel at this year’s BIO-Europe®, taking place in Copenhagen between 5-7 November. Mike Romanos, CEO of Microbiotica, will participate in the Microbiome and the Implication on Other Therapeutic Areas along with panellists from Enterome, Ferring […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2018-10-30 09:00:312020-05-26 14:34:09Microbiotica Participates in Microbiome Panel Discussion at this year’s Bio-Europe®
Seventure Partners, a specialist investor in the microbiome, commits new funding from Health for Life Capital™ and strengthens Microbiotica’s Board with microbiome sector expertise and know-how. Joins founding investors, Cambridge Innovation Capital and IP Group, by committing £4m, bringing total equity raised to £12m. Cambridge, UK, 24 October 2018 – Microbiotica, a leading player in […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2018-10-24 09:00:382020-05-26 14:35:53Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital™ Fund
Cambridge, UK, 18 June 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement with University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis (UC). Financial details have not been disclosed. Microbiotica is collaborating with Dr Sam Costello, Adelaide Medical […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2018-06-18 09:00:112020-05-26 14:37:15Microbiotica Collaborates with University of Adelaide to Develop a Novel Microbial Therapy for Ulcerative Colitis
Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline Utilises Microbiotica’s leading gut microbiome Reference Genome Database and Culture Collection Microbiotica to receive up to $534 million in upfront and milestone payments Cambridge, UK, 6 June 2018 – Microbiotica, a leading player in microbiome-based therapeutics spun out of the […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2018-06-06 09:00:332020-05-26 14:38:47Microbiotica Enters into Microbiome Collaboration with Genentech
Cambridge, UK, 22 May 2018 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it will present at leading microbiome conferences throughout May and June. Microbiome Invest – 23 May, London, UK Dr Mike Romanos, co-founder and CEO of Microbiotica, will join panellists David Cook, Seres Therapeutics and Luc Sterkman, Caelius Therapeutics BV for a […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2018-05-22 09:00:142020-05-26 14:40:31Microbiotica to Present at Top Microbiome Conferences
Cambridge, UK, 25th October 2017 – Microbiotica, a leading player in microbiome-based therapeutics, today announces that Nigel Crockett, Head of Business Development, will participate in the Microbiome panel at the 23rd Annual International Partnering Conference, BIO-Europe®, which will be held from 6-8 November, in Berlin, Germany. The discussion, entitled ‘Targeting the microbiome: From scientific evidence to regulatory […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2017-10-26 09:00:362020-05-26 14:41:14Microbiotica to Participate in Microbiome Panel at BIO-Europe®
Company receives ‘Best Start-up Biotech’ at OBN Awards Cambridge, UK, 11 October 2017 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been awarded UK Best Start-up Biotech at the OBN Awards, which took place at Oxford Town Hall. The award recognises Microbiotica’s commercial potential in the fast-growing microbiome space, […]
https://microbiotica.com/wp-content/uploads/2020/05/logo.png00immunocityhttps://microbiotica.com/wp-content/uploads/2020/05/logo.pngimmunocity2017-10-11 09:00:232020-05-26 14:42:14Microbiotica Celebrates Successful First Year with Third Award Win
Find us on LinkedIn
info@microbiotica.com
Microbiotica Presenting at Key Industry Events during Summer 2019
/in News /by immunocityCambridge, UK, 20 June 2019 – Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference attendance and during summer 2019. CEO Dr Mike Romanos, CSO Dr Trevor Lawley and Head of Bioinformatics Dr Simon Harris will be presenting on commercial and scientific advances and opportunities in the fast-moving microbiome space: Cambridge Biotech […]
Genentech’s Immunology/Infectious Disease Deal Maker On Following The Science
/in News /by immunocityGenentech’s infectious diseases and immunology dealmaker speaks to Scrip about the significance of following the science when it comes to partnering. When reflecting on the licensing deals inked this year by biotech behemoth Genentech Inc., two really stand out: the June deal with microbiome company Microbiotica Ltd. to discover, develop and commercialize treatments for inflammatory […]
Microbiotica Wins Life Sciences Company of the Year at Cambridge Independent Awards
/in News /by immunocityCambridge, UK, 2 November 2018 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been named Life Sciences Company of the Year at the Cambridge Independent Awards, which took place last night at the Hilton Cambridge City Centre Hotel. Microbiotica was recognised for a year of continued development in the fast-growing […]
Microbiotica Participates in Microbiome Panel Discussion at this year’s Bio-Europe®
/in News /by immunocityCambridge, UK, 30 October 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it will join the microbiome panel at this year’s BIO-Europe®, taking place in Copenhagen between 5-7 November. Mike Romanos, CEO of Microbiotica, will participate in the Microbiome and the Implication on Other Therapeutic Areas along with panellists from Enterome, Ferring […]
Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital™ Fund
/in News /by immunocitySeventure Partners, a specialist investor in the microbiome, commits new funding from Health for Life Capital™ and strengthens Microbiotica’s Board with microbiome sector expertise and know-how. Joins founding investors, Cambridge Innovation Capital and IP Group, by committing £4m, bringing total equity raised to £12m. Cambridge, UK, 24 October 2018 – Microbiotica, a leading player in […]
Microbiotica Collaborates with University of Adelaide to Develop a Novel Microbial Therapy for Ulcerative Colitis
/in News /by immunocityCambridge, UK, 18 June 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement with University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis (UC). Financial details have not been disclosed. Microbiotica is collaborating with Dr Sam Costello, Adelaide Medical […]
Microbiotica Enters into Microbiome Collaboration with Genentech
/in News /by immunocityStrategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline Utilises Microbiotica’s leading gut microbiome Reference Genome Database and Culture Collection Microbiotica to receive up to $534 million in upfront and milestone payments Cambridge, UK, 6 June 2018 – Microbiotica, a leading player in microbiome-based therapeutics spun out of the […]
Microbiotica to Present at Top Microbiome Conferences
/in News /by immunocityCambridge, UK, 22 May 2018 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it will present at leading microbiome conferences throughout May and June. Microbiome Invest – 23 May, London, UK Dr Mike Romanos, co-founder and CEO of Microbiotica, will join panellists David Cook, Seres Therapeutics and Luc Sterkman, Caelius Therapeutics BV for a […]
Microbiotica to Participate in Microbiome Panel at BIO-Europe®
/in News /by immunocityCambridge, UK, 25th October 2017 – Microbiotica, a leading player in microbiome-based therapeutics, today announces that Nigel Crockett, Head of Business Development, will participate in the Microbiome panel at the 23rd Annual International Partnering Conference, BIO-Europe®, which will be held from 6-8 November, in Berlin, Germany. The discussion, entitled ‘Targeting the microbiome: From scientific evidence to regulatory […]
Microbiotica Celebrates Successful First Year with Third Award Win
/in News /by immunocityCompany receives ‘Best Start-up Biotech’ at OBN Awards Cambridge, UK, 11 October 2017 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been awarded UK Best Start-up Biotech at the OBN Awards, which took place at Oxford Town Hall. The award recognises Microbiotica’s commercial potential in the fast-growing microbiome space, […]